NRG Oncology RTOG 0625: A Randomized Phase II Trial of Bevacizumab with either Irinotecan or Dose-Dense Temozolomide in Recurrent Glioblastoma

BACKGROUND: Angiogenesis, a hallmark of glioblastoma, can potentially be targeted by inhibiting the VEGF pathway using bevacizumab, a humanized monoclonal antibody against VEGF-A. This study was designed to determine the efficacy and safety of these regimens in the cooperative group setting. METHODS...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Neurooncol
Hlavní autoři: Gilbert, Mark R., Pugh, Stephanie L, Aldape, Ken, Sorensen, A. Gregory, Mikkelsen, Tom, Penas-Prado, Marta, Bukshstein, Felix, Kwok, Young, Lee, R. Jeffrey, Mehta, Minesh
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5263144/
https://ncbi.nlm.nih.gov/pubmed/27770279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-016-2288-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky